Dec. 19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease in a subset of people.

Dec. 19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease in a subset of people.

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.

If you need dementia support, we’re here for you. All calls with the Dementia Support Line are recorded for training and quality purposes. Calls charged at standard local rate. If you are in an ...

In a new discovery in the battle against Alzheimer's disease, scientists have pinpointed a key cellular mechanism that is the primary cause of the neurodegenerative condition. American scientists ...

Wells Fargo says that while the ADVANCE-2 miss makes the regulatory path less certain, the totality of the data supports approval for Axsome Therapeutics (AXSM)’ AXS-05 in Alzheimer’s disease ...

The ADVANCE-2 trial was a double-blind, placebo-controlled, parallel group trial of AXS-05 in Alzheimer’s disease patients with agitation. A total of 408 patients were randomized in a 1:1 ratio ...

The first pill to slow down Alzheimer's disease is being analysed for potential use on the NHS Getty Professor Alistair Burns, former NHS clinical director for dementia, called the trial results ...

For a person living with dementia, being able to use language and communicate clearly can become more difficult over time. While the person living with the condition may have difficulties finding the ...

Alzheimer's disease is a progressive neurodegenerative disease that impairs memory and cognitive judgment and is often accompanied by mood swings, disorientation and eventually delirium.

The decision will follow the mixed fortunes of two breakthrough drugs for Alzheimer’s drugs - Lecanemab and Donanemab - having with UK regulators. Despite both being given the green light by the ...

Dementia is extremely common. According to a 2022 study, a startling 10% of adults in the United States over the age of 65 have dementia, and another 22% have mild cognitive impairment. And ...